ENZA-P Big news Update: LuPSMA and enza improves overall survival

GU Cast | Urology Podcast

#Science #Fitness #Medicine #Dr Renu Eapen #Professor Declan Murphy #Urology #Prostate Cancer #Kidney Cancer #Testis Cancer #Penile Cancer #Gu Oncology #Cancer #Podcasting Education #Professor Declan Murphy And Dr Renu Eapen

39:33

"The basic premise of the event is that hunters hunt rattlesnakes from the surrounding environment all across West Texas, and bring them into the roundup for the weekend. And during the roundup, these snakes are kept in a pit and then, one by one, beheaded and skinned in front of in front of audiences." - Elizabeth MeLampy Elizabeth MeLampy is a lawyer dedicated to animal rights and protection, and her passion for this work shines through in her latest book, Forget the Camel, the Madcap World of Animal Festivals and What They Say About Being Human . To research the book, Elizabeth traveled across the country, immersing herself in a wide range of animal festivals — from the Iditarod dog sled race to the rattlesnake roundup in Sweetwater, Texas. Elizabeth examines these festivals as revealing microcosms of our broader relationship with animals. Whether it's rattlesnake hunts, frog-jumping contests, ostrich races, or groundhog celebrations, these events reflect the ways humans use animals to express cultural identity, community pride, and historical traditions. Yet beneath the pageantry and excitement lies a deeper question: Is our fascination with these spectacles worth the toll it takes on the animals involved? With compassion and insight, Elizabeth invites readers to consider whether there’s a more ethical and empathetic way to honor our stories — one that respects both animals and the traditions they inspire. Please listen, share and read, Forget the Camel. It will be released on April 8th, 2025. https://apollopublishers.com/index.php/forget-the-camel/…

about a year ago 29:36

MP3•Episode home

A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!! A 45% reduction in the risk of death in favour of the combination. Plus excellent quality of life for those receiving the combo.
We are joined by Louise and co-author A/Prof Andrew Weickhardt (Austin Health, Melbourne), to discuss this exciting data from the ENZA-P trial, and what it means for the future of not just mCRPC, but also for similar combinations in mHSPC.
ENZA-P is an investigator-initiated Phase II trial led by ANZUP in partnership with the Prostate Cancer Research Alliance, a join initiative between the Australian Government and Movember.
Your co-hosts as ever are Professor Declan Murphy and Dr Renu Eapen.
This is a Themed podcast supported by our Gold Partners, Astellas, and our Silver Partners, Novartis.
Even better on our YouTube channel
Links:
Lancet Oncology paper
ANZUP

174 episodes

ENZA-P Big news Update: LuPSMA and enza improves overall survival

GU Cast | Urology Podcast

12 subscribers

published about a year ago

MP3•Episode home

174 episodes

All episodes

1
Neurosaving erectile function - a new dawn for nerve-sparing prostatectomy 39:56

3 days ago39:56

39:56

Really big prostate cancer news today with the release of very interesting results from the Neurosafe Proof trial at the EAU Annual Meeting in Madrid. Also simultaneously published in Lancet Oncology so this is a big deal!! In summary, this multi centre randomised trial from the UK demonstrates that men undergoing the Neurosafe technique (intra-operative assessment of surgical margins), had higher rates of nerve sparing surgery and this in turn led to improvements of recover of sexual function. We were delighted to have a detailed discussion on this with key members of the University College London team who led this trial - Prof Greg Shaw, Dr Eoin Dinneen, and Dr Ricardo Almeida-Magana. This is a Themed Podcast supported by our Gold Partner, Mundipharma Even better on our YouTube channel Links: Full paper in Lancet Oncology Funders: National Institute for Health Research JP Poulton Charitable Foundation Rosetree Trust Orchid…

1
The end of the road for TRUS biopsy? Translate trial reads out 40:25

4 days ago40:25

40:25

We are delighted to drop this pod just as the landmark TRANSLATE trial reads out at the EAU Annual Meeting in Madrid, with a simultaneous publication in Lancet Oncology. This is the world's largest trial of transrectal vs transperineal (TP) prostate biopsy, and reports that TP biopsy has superior cancer detection ability. Is this the end of the road for TRUS biopsy. Hosts Declan Murphy and Renu Eapen are delighted to welcome first and senior authors, Prof Richard Bryant and Dr Alastair Lamb of the University of Oxford to have a detailed discussion about TRANSLATE and what this means for prostate biopsy. `Even better on our YouTube channel Links: Lancet Oncology paper Funders:…

1
GU Cast in Shanghai | Prostate Cancer in China in 2025 32:31

8 days ago32:31

32:31

Declan Murphy is in the GU Cast studio in Shanghai with GU Cast China Editor, Prof Yao Zhu. We sit down with Prof Hao Zeng (West China Hospital) and Dr Ye Yan to discuss their experiences and perspectives on advancements in diagnostics like MRI and PSMA PET, the increasing use of Chinese-developed robotic surgery platforms, and the ongoing debate surrounding pelvic lymph node dissection. They also address the application of systemic therapies for metastatic disease, considering the unique characteristics of the Chinese patient population and the potential for dose adjustments. Today's pod also highlights the growing importance of precision oncology, including genomic testing for mutations to guide treatment decisions, while acknowledging the challenges and future directions in this area. This is a Themed Podcast supported by our Gold Partner, Bayer China. Even better on our YouTube channel https://youtu.be/xlOuS4swcuc…

1
Meet the Quokkas!! #USANZ25 Conference Highlights 46:21

11 days ago46:21

46:21

This week we had the great pleasure of attending the Annual Scientific Meeting of the Urological Society of Australia and New Zealand (USANZ), which took place in the beautiful city of Perth, far out on the West Coast of Australia. Not just that, but we spent a wonderful afternoon on one of Australia’s top tourist attractions, Rottnest Island. Tune in for plenty of quokka action! Plus, of course we bring you some great conference highlights, chatting with international guests, including Laura Bukavina, Alberto Breda, Samir Taneja, plus Australian guests, Nathan Lawrentschuk, Michael Chamberlain, and Scientific Convener Trenton Barrett. GU Cast conference highlights are brought to you by our Conference Highlights partner, Bayer China. Even better on our YouTube channel (check out Rottnest Island and the Quokkas)!!…

1
Biochemical recurrence | With Steve Freedland 41:24

21 days ago41:24

41:24

A fantastic episode for urologists, radiation oncologists, and anyone interested in localised prostate cancer. Biochemical recurrence (BCR) is unfortunately all too common after surgery or radiation for prostate cancer, and today we talk with someone who has been working in BCR for more than 20 years. Dr Steve Freedland, Urologist at Cedars-Sinai in Los Angeles, popped into the GU Cast studio to talk about the landmark series from Johns-Hopkins Medical Institute (links below) which still today remains our best guide to the natural history of BCR after radical prostatectomy. And the key message that PSA doubling time is our most important tool to risk stratify patients reminds true today. And Steve of course is the lead investigator of the EMBARK trial, published in NEJM in 2023, which has led to a new standard of care for men experiencing high-risk BCR after surgery or radiotherapy. EMBARK has clearly shown us that the use of enzaluamide, either on its own, or with androgen deprivation therapy, reduces the risk of metastases when compared with ADT alone. We dive deep into EMBARK with Steve. This is a Themed Podcast supported by our Gold Partners, Astellas. Astellas also supported Steve to be in Australia this week for the USANZ ASM in Perth, and visits to Melbourne and Sydney. Your hosts are Professor Declan Murphy and Dr Renu Eapen. Even better on our Youtube channel Links: Freedland et al JAMA 2005 EMBARK paper in NEJM…

1
Fellowship fun in Australia (and some prostate cancer chat)! 25:45

28 days ago25:45

25:45

Two great international visitors recently led to two great sets of podcast chats!! Dr Kim Chi (Vancouver), and Dr Carmen Mir (Valencia) were in Melbourne to speak at the PROSPECT Meeting (see links below). We grabbed Kim along with Prof Arun Azad (Peter MacCallum Cancer Centre, Melbourne), and Dr Louise Kostos (also Peter Mac), to overlook some hot topics in mHSPC. And then a cracking chat with Carmen along with two Europeans doing Urology Fellowship training in Melbourne - Dr Christa Babst (Peter MacCallum Cancer Centre/Switzerland), and Dr Marta Alves (Royal Melbourne Hospital/Barcelona). Carmen had also done a Fellowship in Melbourne at Austin Health so could give some great perspectives. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson, who also supported the recent PROSPECT meeting. Even better on our YouTube channel Links: PROSPECT podcast Part 1 PROSPECT Podcast Part 2…

1
ENZA-P Big news Update: LuPSMA and enza improves overall survival 29:36

6 weeks ago29:36

29:36

A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!! A 45% reduction in the risk of death in favour of the combination. Plus excellent quality of life for those receiving the combo. We are joined by Louise and co-author A/Prof Andrew Weickhardt (Austin Health, Melbourne), to discuss this exciting data from the ENZA-P trial, and what it means for the future of not just mCRPC, but also for similar combinations in mHSPC. ENZA-P is an investigator-initiated Phase II trial led by ANZUP in partnership with the Prostate Cancer Research Alliance, a join initiative between the Australian Government and Movember. Your co-hosts as ever are Professor Declan Murphy and Dr Renu Eapen. This is a Themed podcast supported by our Gold Partners, Astellas, and our Silver Partners, Novartis. Even better on our YouTube channel Links: Lancet Oncology paper ANZUP…

1
Future-gazing radioligand therapy in prostate cancer | With Oliver Sartor and Michael Hofman 37:27

8 weeks ago37:27

37:27

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer. We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business. Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne. This is a Themed Podcast supported by our Silver Partners, Novartis. Even better on our YouTube channel Links: Michael's paper in the Journal of Nuclear Medicine :"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"…

1
Toni's Legendary Top 10 Papers List! 48:48

10 weeks ago48:48

48:48

Dr Toni Choueiri, Chief of GU Oncology at Dana-Farber Cancer Institute (Boston, USA) returns to GU Cast with members of his team at Dana Farber Cancer Institute to discuss our favourite lists of top GU Oncology papers for 2024. Toni has posted these now legendary lists at the end of each year on Twitter/X since the start of Covid, and they have become essential reading for anyone wanting a superb overview of top trials. Each tweet contains a top line summary of each trial and key images such as K-M curves, plus links to the original papers. A huge amount of work and a great resource. Today we are joined by Toni along with Dr Marc Eid and Dr Emre Yekeduz who helped compile this year's lists. We hear about the process behind it all, and we run through their Top 10 Bladder and Renal Cancer papers, and their Top 5 Prostate Cancer papers. The team also post their Top 10 Translational papers and Their Top 10 non-GU Oncology papers. Well done again to Toni, Marc, Emre and team! Links to the tweets below. Even better on our YouTube channel Links: Top 10 Bladder and Renal Cancer Papers Top 5 Prostate Cancer Papers…

1
Shanghai GU Oncology Highlights Part 2 40:53

11 weeks ago40:53

40:53

Part 2 of our GU Cast Conference Highlights from Shanghai including discussions with Dr Stephen Freedland (Los Angeles), Dr Liang Liang (Shaanxi), Dr Andrea Necchi (Milano), Dr Xiaojie Bian (Shanghai), and Dr Hongkai Wang (Shanghai). Declan Murphy travelled to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities. In Part 1 we spoke to Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger, to overview the latest stories in GU Oncology. Special thanks to our Conference Highlights Partner, Bayer China, who set up an amazing GU Cast studio for us in Shanghai. Thanks to Hexun and all the local Bayer team in China. Also available as an audio podcast - just search GU Cast wherever you get your podcasts…

1
Shanghai GU Oncology Highlights Part 1 35:11

12 weeks ago35:11

35:11

Declan Murphy travels to Shanghai for the 14th GU Oncology Academic Meeting hosted by Fudan University Shanghai Cancer Centre, and to meet up with our GU Cast China Editor, Dr Yao Zhu. This is an excellent meeting in one of our very favourite cities, and this year Declan joins International Faculty including Dr Stephen Freedland (Los Angeles), Dr Karim Fizazi (Paris), Dr Axel Merseburger (Lubeck). and Dr Andrea Necchi (Milano) to overview the latest stories in GU Oncology. Top Chinese experts from across the country also join and the meeting includes some landmark consensus statements from multidisciplinary panels. Today we post Part 1 of our GU Cast Conference Highlights from Shanghai including discussions with Conference Chair, Dr Dingwei Ye, Dr Karim Fizazi, Dr Peng Wu, and Dr Axel Merseburger. Special thanks to our Conference Highlights Partner, Bayer China, who set up an amazing GU Cast studio for us in Shanghai. Thanks to Hexun and all the local Bayer team in China. Even better on our YouTube channel…

1
Stories of single-port surgery (and cricket) 33:58

13 weeks ago33:58

33:58

Our final episode of the year! And we end with a very seasonal celebration of single-port surgery and the Boxing Day Test with Australia playing India in one of the world's most famous cricket matches. We coaxed Dr Mihir Desai (University of Southern California, Los Angeles) and A/Prof Daniel Moon (Peter Mac, Melbourne) out of the Melbourne Cricket Ground and into our nearby studio at the close of play on Day 2 to talk all things single-port surgery (and cricket). Cricket-mad Mihir flew in from LA to tick off his bucket list ambition of attending a Boxing Day Test. We reminisce about the early days of single-port laparoscopy and talk about what robotic surgery does (and does not) bring to single-port surgery. Plus we remember the day that Indy Gill met Shane Warne at the MCG ten years ago while attending a meeting here! Two legends of their games. And to end season 5 of GU Cast, your hosts Declan Murphy and Renu Eapen thank our amazing Partners for supporting our ever expanding pool of content from GU Cast. Even better on our YouTube channel Links: BJUi Blog about when Indy met Warnie…

1
A Dummy's Guide to Metastatic Renal Cancer!! 37:49

16 weeks ago37:49

37:49

Have you ever found the choice of agents in metastatic kidney cancer just a bit perplexing??! Well then this is the podcast for you! To celebrate a fantastic review paper recently published in European Urology, we chat with first author Dr Regina Barragan-Carillo (City of Hope, California), and second senior author Dr Tian Zhang (UT South-Western, Texas). The title of the paper is "First and Second-line Treatments in Metastatic Renal Cell Carcinoma", and it's about the best paper we have read on this topic, with a proper who's who in renal cancer contributing. Plus completely up to date with a literature review up to October 2024. Co-hosts Declan Murphy and Renu Eapen really enjoyed this one! This is a Themed Podcast supported by our Bronze Partner, Ipsen Pharmaceuticals. Even better on our YouTube channel Links: European Urology paper (paywall)…

1
The Sir Chris Hoy Effect | Why family history matters 29:52

18 weeks ago29:52

29:52

Legendary British cyclist Sir Chris Hoy (48) recently shocked the world by announcing that he has progressive metastatic prostate cancer. His specialists have given him a 2-4 year life expectancy. The dreadful news that no prostate cancer patient wants to hear. Today, hosts Prof Declan Murphy and Dr Renu Eapen welcome their good mates A/Prof Ben Challacombe (Guy's Hospital, London), and A/Prof Daniel Moon (Peter MacCallum Cancer Centre, Melbourne) to the GU Cast studio, and patient advocate Andrei Norris who joins on Zoom to discuss the huge publicity this has generated, and the importance of family history in assessing men's risk of prostate cancer. This is a Themed Podcast supported by our Silver Partners, Bayer Pharmaceuticals. Even better on our YouTube channel…

1
PLND, ARPI Switch & De-Escalation | PROSPECT Podcast part 2 37:11

19 weeks ago37:11